Hybrid humoral immune response of Pacific Islanders to BNT162b2 vaccination and Delta/Omicron infection: a cohort study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination strategies adapted to Pacific Islanders singularities.
Methods
We evaluated the humoral immune response of 585 adults self-declaring as Melanesians, Europeans, Polynesians or belonging to other communities to Pfizer BNT162b2 vaccine. Anti-Spike and anti-Nucleoprotein IgG levels, capacity to neutralize SARS-CoV-2 variants and capacity to mediate Antibody-Dependent Cellular Cytotoxicity (ADCC) were assessed across communities at one and three months post-second dose or one and six months post-third dose.
Results
61.3% of the sera tested contained anti-Nucleoprotein antibodies, evidencing mostly a hybrid immunity resulting from vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels and capacity to mediate Omicron neutralization and ADCC were equivalent across the four ethnic communities at one-month post-immunization, during follow-up and at six months post-third dose, regardless of the infection status. Obese individuals (BMI>30 kg/m²) had significantly higher anti-Spike IgG levels at one-month post-immunization (+0.26 (0.04; 0.48) AU in LuLISA assay, p value = 0.017). Odds of Omicron neutralization at six months after the third dose decreased significantly in the 40-64 years and ≥65 years groups (OR (95% CI) 0.48 (0.24-0.90) and 0.29 (0.14-0.58) respectively, p -value = 0.003).
Conclusions
Our study evidenced Pacific Islander’s robust humoral immune response to Pfizer BNT162b2 vaccine, which is pivotal to re-enforce vaccination deployment in a population at risk for severe COVID-19 (clinicaltrials.gov: NCT05135585 ).
summary
Ethnicity has little impact on Pacific Islanders’ hybrid humoral immune response to BNT162b2 vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels, capacity to neutralize Omicron variants and capacity to mediate Antibody-Dependent Cellular Cytotoxicity are equivalent across Pacific communities following BNT162b2 vaccination.
